Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRA | P11474 | 12/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | PIM1 | P11309 | 2/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.56 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.56 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.56 |
| ▸ | ESRRB | O95718 | 1/20 | 0.54 |
| ▸ | ESR1 | P03372 | 1/20 | 0.54 |
| ▸ | ESRRG | P62508 | 1/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.54 |
| ▸ | FOXM1 | Q08050 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 3/20 | 0.50 |
| ▸ | IGF1R | P08069 | 1/20 | 0.50 |
| ▸ | CDC7 | O00311 | 1/20 | 0.50 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.50 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.50 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.50 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14492770 | 1.00 | ESRRA (0.58) | ESRRACYP3A4PIM1PDE4BPIM3 | |
| SCHEMBL5493517 | 1.00 | ESRRA (0.58) | ESRRACYP3A4PIM1PDE4BPIM3 | |
| SCHEMBL7468327 | 0.92 | ESRRA (0.58) | ESRRACYP3A4PIM1PDE4BPIM3 | |
| SCHEMBL7468330 | 0.92 | ESRRA (0.58) | ESRRACYP3A4PIM1PDE4BPIM3 | |
| SCHEMBL14492773 | 0.91 | RXRA (0.56) | ESRRACYP3A4PIM1PDE4BPIM3 | |
| SCHEMBL5486039 | 0.91 | RXRA (0.56) | ESRRACYP3A4PIM1PDE4BPIM3 | |
| SCHEMBL5486040 | 0.91 | RXRA (0.56) | ESRRACYP3A4PIM1PDE4BPIM3 | |
| SCHEMBL5491435 | 0.87 | ESRRA (0.48) | ESRRACYP3A4PIM1PIM2ESRRB | |
| SCHEMBL5491428 | 0.87 | ESRRA (0.48) | ESRRACYP3A4PIM1PIM2ESRRB | |
| SCHEMBL14492771 | 0.87 | ESRRA (0.48) | ESRRACYP3A4PIM1PIM2ESRRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1214304-B1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | INCYTE SAN DIEGO INC (US) | 2005-08-24 | — | — | EP | claimed |
| US-6515003-B1 | Useful in the treatment of diseases related to lipid and carbohydrate metabolism | MAXIA PHARMACEUTICALS, INC. | 2003-02-04 | — | — | US | claimed |
| EP-1214304-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | Maxia Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | claimed |
| WO-2001016122-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | MAXIA PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| US-7226940-B2 | Substituted heterocycles for the treatment of diabetes and other diseases | INCYTE SAN DIEGO, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-20060004059-A1 | Substituted heterocycles for the treatment of diabetes and other diseases | PFAHL MAGNUS | 2006-01-05 | — | — | US | disclosed |
| US-6974826-B2 | Imidazolidinedione derivatives for the treatment of diabetes and other diseases | INCYTE SAN DIEGO INC. (US) | 2005-12-13 | — | — | US | disclosed |
| EP-1593677-A2 | Benzylidene-thiazolidinediones and analogues and their use in the treatment of diabetes | Incyte San Diego Incorporated (US) | 2005-11-09 | — | — | EP | disclosed |
| EP-1214304-B1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | INCYTE SAN DIEGO INC (US) | 2005-08-24 | — | — | EP | disclosed |
| US-20050070581-A1 | Imidazolidinedione derivatives for the treatment of diabetes and other diseases | INCYTE SAN DIEGO, INC. | 2005-03-31 | — | — | US | disclosed |
| US-6765013-B2 | ANTIPROLIFERATIVE AGENTS FOR TREATING ADIPOCYTE DIFFERENTIATION, CANCER, OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, CROHN'S DISEASE OR INFLAMMATORY BOWEL DISEASE | INCYTE SAN DIEGO | 2004-07-20 | — | — | US | disclosed |
| US-20030153606-A1 | Thiazolidinedione derivatives for the treatment of diabetes and other diseases | MAXIA PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
| US-6515003-B1 | Useful in the treatment of diseases related to lipid and carbohydrate metabolism | MAXIA PHARMACEUTICALS, INC. | 2003-02-04 | — | — | US | disclosed |
| EP-1214304-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | Maxia Pharmaceuticals, Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001016122-A1 | BENZYLIDENE-THIAZOLIDINEDIONES AND ANALOGUES AND THEIR USE IN THE TREATMENT OF DIABETES | MAXIA PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004059-A1 | Substituted heterocycles for the treatment of diabetes and other diseases | FABP4, HPGDS, GPR119 | ESRRA 352/4885CYP3A4 779/4885PIM1 2383/4885 |
| US-20030153606-A1 | Thiazolidinedione derivatives for the treatment of diabetes and other diseases | FABP4, PPARG, CPT2 | ESRRA 336/4885CYP3A4 311/4885PIM1 2030/4885 |
| US-20050070581-A1 | Imidazolidinedione derivatives for the treatment of diabetes and other diseases | FABP4, GPR119, IL2 | ESRRA 671/4885CYP3A4 600/4885PIM1 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.